Efficacy and Safety of 1% Terbinafine Film-Forming Solution Single Application versus 1% Clotrimazole Cream Standard Dose in the Treatment of Tinea Pedis in Correctional Setting

开始日期2025-06-01

申办/合作机构-

NCT06400056

/ Not yet recruiting临床1期IIT

Clinical and Laboratory Evaluation of Antifungal Resistance in Tinea Capitis

AIM OF WORK :
1. Detect the most common fungal strains that cause tinea capitis
2. Detect Different effectiveness of terbinafine in different cases
3. Detect the resistant strains.
4. Detect the mycological and the clinical cure rates upon using systemic terbinafine in treatment of tinea capitis

开始日期2024-05-01

申办/合作机构

Assiut University

IRCT20240225061105N1

/ Recruiting临床2期IIT

Comparison of the Effect of Terbinafine alone with the Combination of Terbinafine and Prednisolone in the Treatment of Inflammatory Tina Capitis

开始日期2023-11-15

申办/合作机构

Kermanshah University of Medical Sciences

100 项与盐酸特比萘芬相关的临床结果

登录后查看更多信息

100 项与盐酸特比萘芬相关的转化医学

登录后查看更多信息

100 项与盐酸特比萘芬相关的专利（医药）

登录后查看更多信息

2,805

项与盐酸特比萘芬相关的文献（医药）

2025-06-01·CURRENT MICROBIOLOGY

Fungal Infections Resulting From Prolonged Use of Personal Protective Equipment

Article

作者: Berikten, Derya ; Aydin, Elif ; Renders, Duygu Percin ; Utku, Selve Arslan

This study is the first to investigate fungal infections resulting from prolonged use of personal protective equipment (PPE) among healthcare workers at Kütahya Health Sciences University Evliya Çelebi Training and Research Hospital, during the COVID-19 pandemic. The research aimed to isolate, molecularly type, and assess the antifungal susceptibility of superficial fungal infection agents associated with PPE use. Additionally, the relationship between these fungi and PPE use was evaluated through a questionnaire. Samples were collected from 100 healthcare workers experiencing skin issues. Among them, all N95/FFP2 mask users, 44.3% of glove users, 36.1% of surgical mask users, and 22.9% of hair cap users reported skin reactions, with acne (n = 34) being the most common. Identified fungal isolates included Trametes hirsuta, Penicillium chrysogenum, Aspergillus fumigatus, Rhodotorula sp., Candida sp., Pichia fermentans, and the dermatophyte Microsporum ferrugineum. Antifungal susceptibility tests revealed 47.6% resistance to fluconazole and 76.2% resistance to voriconazole (n = 16). This study provides the first institutional data on PPE-associated fungal infections and antifungal resistance in healthcare settings. These findings highlight the dermatological risks of prolonged PPE use. To mitigate these effects, healthcare institutions should prioritize high-quality materials, establish optimal usage guidelines, and provide continuous training on self-protection.

2025-05-04·Expert Opinion On Drug Safety

Compartment syndrome associations with drugs: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)

Article

作者: Yang, Xueting ; Shu, Yunfeng ; Tang, Juan ; Wan, Jie ; Kong, Wenqiang

BACKGROUND:

Compartment syndrome is an uncommon but life-threatening condition. No study has comprehensively compared compartment syndrome (CS) association with available drugs. The objective of this study was to estimate the association between CS and drugs using the FDA Adverse Event Report System (FAERS).

RESEARCH DESIGN AND METHODS:

FAERS reports from the first quarter of 2004 to the third quarter of 2023 were analyzed. The Medical Dictionary for Regulatory Activities (MedDRA) was used to identify CS cases. Reporting odds ratio (ROR), corresponding to 95% confidence intervals (95% CI) were calculated to detect a positive signal.

RESULTS:

A total of 2197 reports were considered in the study after the inclusion criteria were applied. Totally 100 drugs were found to be associated with CS. The median time for drug-associated CS was 45 days.

CONCLUSIONS:

By analyzing the FAERS database, the study revealed that certain drugs are significantly associated with compartment syndrome. Further studies are needed to verify whether these drugs are associated with such a risk.

2025-05-01·JOURNAL OF BASIC MICROBIOLOGY

Autophagy Activated by Atg1 Interacts With Atg9 Promotes Biofilm Formation and Resistance of Candida albicans

Article

作者: Wei, Xin ; Chen, Xueyi ; Liu, Siqi ; Yu, Shenjun ; Zhao, Xiao ; Huang, Yun

ABSTRACT:

Autophagy regulates the development of Candida albicans (C. albicans) biofilms and their sensitivity to antifungals. Atg1, a serine/threonine protein kinase, recruits autophagy‐related proteins for autophagosome formation. Atg9, the only transmembrane protein, is phosphorylated by Atg1 during autophagy. The specific roles of Atg1 and Atg9 in biofilm formation and resistance of C. albicans remain unclear. The study used RT‐qPCR and Western blotting to assess the correlation between Atg1, Atg9 and biofilm formation, XTT reduction assays to evaluate biofilm formation and antifungal resistance, commercial kits to detect reactive oxygen species (ROS), mitochondrial membrane potential (MMP), and autophagy activity, transmission electron microscopy (TEM) to study the morphological changes, protein–protein interaction (PPI) analysis to analyze the interaction between Atg1 and Atg9. Results demonstrated that Atg1 and Atg9 were highly expressed in biofilms than planktonic cells. Biofilm formation, antifungal resistance, MMP and autophagy activity decreased and ROS increased in atg1Δ/Δ and atg9Δ/Δ. TORC1 inhibition with rapamycin rescued the reduced biofilm formation of atg1Δ/Δ and increased antifungal resistance of atg1Δ/Δ and atg9Δ/Δ. PPI analysis and TEM observation indicated that Atg1 interacted with Atg9, which was certified by RT‐qPCR and Western blotting. This study suggested that Atg1 interacts with Atg9, activates the autophagy regulating the formation and sensitivity of C. albicans biofilms.

103

项与盐酸特比萘芬相关的新闻（医药）

2025-06-16

·mobergpharma.com

Terclara market leader also in Norway

Terclara® was launched in Norway in collaboration with our partner Allderma. “We are proud to announce that the Norwegian success follows the highly successful Swedish launch and is built on the same proven model: a combination of broad distribution via all pharmacy chains, targeted marketing and close collaboration with heath care professionals and the pharmacy sector.” says Mimmi Frölén, CEO of Allderma. As consumer sell-out data is not reported in Norway, the market leadership is based on sell-in data to pharmacies. Terclara® recorded the highest sell-in within its segment both in May (market share: 48% by value, 45% by units) and April (38% by value, 35% by units). As in Sweden last year, the launch in Norway was timed ahead of peak season, with pharmacy deliveries beginning in February and consumer marketing starting at the end of March 2025. Despite the short time since launch, Terclara® has already achieved market leadership for the full period January–May 2025, with a market share of 32% by value and 29% by units.[1] "We are very pleased to have already achieved our goal of becoming the market leader also in Norway," says Anna Ljung, CEO of Moberg Pharma. "This is clear evidence that our launch strategy is working and that demand for effective topical treatments is strong across multiple markets." For additional information, please contact: Anna Ljung, CEO, telephone: +46 70 766 60 30, e-mail: anna.ljung@mobergpharma.se About this information The information was submitted for publication, through the agency of the contact person set out above, on June 16th, 2025, at 8.00 am CEST. About Moberg Pharma, www.mobergpharma.com Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's drug MOB-015 is a novel topical treatment for onychomycosis (nail fungus) with market approval in 13 EU countries. MOB-015 is sold in Sweden and Norway under the brand name Terclara® and is available at all pharmacy chains. Phase 3 clinical trials for MOB-015 involving more than 800 patients indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the company's shares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB). About Allderma Pharmaceuticals, www.allderma.se Allderma Pharmaceuticals is a Swedish pharmaceutical company that since 2001 develops, sells and markets over the counter and self-care products. The range spans a number of different treatment areas, with a focus and expertise in dermatology. Founder Hans Svartholm started Allderma after working in the pharmaceutical industry for many years. The idea was simple and still applies it should be easy to find an effective and safe product for the most common skin problems. Allderma emphasis and invests in information for healthcare providers, pharmacists, doctors and consumers. Product specialists work continuously to be a spear head in research and innovation within dermatology. Allderma has been part of 3iM Invest AB's investment area Consumer Healthcare since 2020. [1] Source: IQVIA MIDAS, Pharmacy Sell-In data, Jan-May 2025

临床3期上市批准

2025-06-03

·mobergpharma.com

The board of directors exercises authorizations to issue and repurchase C-shares, and converts class C shares to common shares

The annual general meeting of Moberg Pharma AB (publ) on 22 May 2025 resolved – for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programme LTI 2025 resolved by the annual general meeting and for the purpose of covering certain costs, primarily social security costs, that may arise as a result of incentive programs – to authorize the board of directors to resolve on a directed share issue of redeemable- and convertible class C shares. The general meeting also resolved to authorize the board of directors to resolve on the repurchase of all issued class C shares by an offer directed to all holders of class C shares. Repurchase under this authorization may be made on one or several occasions until the next annual general meeting and at a price not less than 100 per cent and no more than 105 per cent of the quotient value of the share of approximately SEK 1. The board of directors resolved to exercise the share issue authorization for the said purpose to issue 832,213 class C shares to Vator Securities AB. The share issues shall be made at a price corresponding to the quotient value of the share and must be subscribed for within three weeks from the day of the resolution on the new issue. The board of directors has the right to extend the subscription period. The board of directors has resolved to exercise the repurchase authorization for the said purpose by repurchasing all issued class C shares against payment corresponding to 100 per cent of the quota value of the share, corresponding to approximately SEK 1 per share. Repurchase of the class C shares may be effected no later than on August 31st 2025. The class C shares will, following the repurchase, be converted to common shares to secure the delivery under the incentive programme. The company currently holds 879,227 own common shares. After repurchase and conversion of C-shares in accordance with the above, the number of own common shares held will amount to 1,711,440. For additional information, please contact: Anna Ljung, CEO, telephone: +46 70 766 60 30, e-mail: anna.ljung@mobergpharma.se Mark Beveridge, Vice President Finance, telephone: +46 76 805 82 88, e-mail: mark.beveridge@moberpharma.se About this information The information was submitted for publication at 1:30 pm CEST on June 3rd 2025 through the contact persons above. About Moberg Pharma, www.mobergpharma.com Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's drug MOB-015 is a novel topical treatment for onychomycosis (nail fungus) with market approval in 13 EU countries. MOB-015 is sold in Sweden and Norway under the brand name Terclara® and is available at all pharmacy chains. Phase 3 clinical trials for MOB-015 involving more than 800 patients indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the company's shares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB).

临床3期

2025-05-05

·信狐药迅

百济神州BCL-2抑制剂索托克拉提交上市申请|新受理（4.27-5.5）

本周药品注册受理数据，分门别类呈现，一目了然。(4.27-5.5）新药上市申请药品名称企业注册分类受理号索托克拉片百济神州(苏州)生物科技有限公司1CXHS2500043索托克拉片百济神州(苏州)生物科技有限公司1CXHS2500042索托克拉片百济神州(苏州)生物科技有限公司1CXHS2500041索托克拉片百济神州(苏州)生物科技有限公司1CXHS2500040左氨氯地平比索洛尔片(Ⅱ)施慧达药业集团(吉林)有限公司2.3CXHS2500039左氨氯地平比索洛尔片(Ⅰ)施慧达药业集团(吉林)有限公司2.3CXHS2500038新药临床申请药品名称企业注册分类受理号注射用HRS8179北京盛迪医药有限公司1CXHL2500436HRS-1893片山东盛迪医药有限公司1CXHL2500431MDI-1228_mesylate凝胶迈英诺医药科技(珠海)有限公司1CXHL2500435MDI-1228_mesylate凝胶迈英诺医药科技(珠海)有限公司1CXHL2500434MDI-1228_mesylate凝胶迈英诺医药科技(珠海)有限公司1CXHL2500433MDI-1228_mesylate凝胶迈英诺医药科技(珠海)有限公司1CXHL2500432SYN608片杭州圣域生物医药科技有限公司1CXHL2500430SYN608片杭州圣域生物医药科技有限公司1CXHL2500429DF-003胶囊上海药苑生物科技有限公司1CXHL2500428DF-003胶囊上海药苑生物科技有限公司1CXHL2500427DF-003胶囊上海药苑生物科技有限公司1CXHL2500426G201-Na胶囊石家庄以岭药业股份有限公司1CXHL2500425G201-Na胶囊石家庄以岭药业股份有限公司1CXHL2500424ABP-745片杭州新元素药业有限公司1CXHL2500418ABP-745片杭州新元素药业有限公司1CXHL2500417ABP-745片杭州新元素药业有限公司1CXHL2500416177Lu-HX02注射液核欣(苏州)医药科技有限公司1CXHL2500413WS-019湖北午时药业股份有限公司2.2CXHL2500415雷美替胺双释片南京三迭纪医药科技有限公司2.2CXHL2500420OLP-210片深圳奥礼生物科技有限公司2.2CXHL2500423OLP-210片深圳奥礼生物科技有限公司2.2CXHL2500422OLP-210片深圳奥礼生物科技有限公司2.2CXHL2500421GBI268注射液苏州智耀生物科技有限公司2.2CXHL2500414甲磺酸阿帕替尼片江苏恒瑞医药股份有限公司2.4CXHL2500419FL115注射液苏州复融生物技术有限公司1CXSL2500350BAT4406F注射液百奥泰生物制药股份有限公司1CXSL2500349人脐带间充质干细胞注射液深圳市北科生物科技有限公司1CXSL2500348注射用BGB-B3227广州百济神州生物制药有限公司1CXSL2500347注射用重组病毒巨噬细胞炎性蛋白广州弘润生物科技有限公司1CXSL2500346靶向CD19和CD22 的嵌合抗原受体自体T细胞注射液上海医药集团生物治疗技术有限公司1CXSL2500344注射用YL242苏州宜联生物医药有限公司1CXSL2500343IMD101 注射液上海英脉德医疗科技有限公司1CXSL2500339BBT001注射液杉竹曜(北京)生物医药科技有限公司1CXSL2500342NouvNeu004睿健毅联医药科技(成都)有限公司1CXSL2500341注射用SKB518四川科伦博泰生物医药股份有限公司1CXSL2500334PM8002注射液普米斯生物技术(珠海)有限公司1CXSL2500333注射用DB-1311映恩生物制药(苏州)有限公司1CXSL2500337注射用BL-B01D1成都百利多特生物药业有限责任公司1CXSL2500332依沃西单抗注射液康方赛诺医药有限公司2.2CXSL2500345SHR-8068注射液苏州盛迪亚生物医药有限公司2.2CXSL2500340SHR-8068注射液苏州盛迪亚生物医药有限公司2.2CXSL2500338贝伐珠单抗注射液苏州盛迪亚生物医药有限公司2.2CXSL2500336阿得贝利单抗注射液上海盛迪医药有限公司2.2CXSL2500335仿制药申请药品名称企业注册分类受理号碳酸司维拉姆干混悬剂金陵药业股份有限公司南京金陵制药厂3CYHS2501638美洛昔康注射液浙江圣兆药物科技股份有限公司3CYHS2501635硫代硫酸钠注射液海南卓科制药有限公司3CYHS2501634复方电解质醋酸钠注射液浙江赛默制药有限公司3CYHS2501623法莫替丁注射液山东新华制药股份有限公司3CYHS2501619坎地氢噻片桂林华信制药有限公司3CYHS2501617重酒石酸间羟胺注射液上海现代哈森(商丘)药业有限公司3CYHS2501612复合磷酸氢钾注射液河北天成药业股份有限公司3CYHS2501611布美他尼注射液国药集团容生制药有限公司3CYHS2501608盐酸利多卡因凝胶舒美奇成都生物科技有限公司3CYHS2501605盐酸倍他司汀片锦州九泰药业有限责任公司3CYHS2501601小儿多种维生素注射液(13)合肥市未来药物开发有限公司3CYHS2501600螺内酯口服混悬液成都倍特得诺药业有限公司3CYHS2501599复方聚乙二醇(3350)电解质口服溶液澳诺(中国)制药有限公司3CYHS2501587富马酸氯马斯汀口服溶液广东华南药业集团有限公司3CYHS2501592苯溴马隆片浙江江北药业有限公司3CYHS2501591琥珀酸亚铁片陕西巨成生物医药生产力促进中心有限公司3CYHS2501589磷酸奥司他韦颗粒重庆万霖生物医药科技有限公司3CYHS2501595沙库巴曲缬沙坦钠片山东新华制药股份有限公司4CYHS2501636布瑞哌唑片北京仁众药业有限公司4CYHS2501628盐酸奥洛他定滴眼液广州维奥康药业科技有限公司4CYHS2501637盐酸特比萘芬喷雾剂四川美大康华康药业有限公司4CYHS2501633硫酸特布他林雾化吸入用溶液云南龙海天然植物药业有限公司4CYHS2501632注射用阿立哌唑丽珠集团丽珠制药厂4CYHS2501631骨化三醇软胶囊浙江华润三九众益制药有限公司4CYHS2501630二甲双胍恩格列净片(I)北京康立生医药技术开发有限公司4CYHS2501629厄贝沙坦氢氯噻嗪片广州白云山天心制药股份有限公司4CYHS2501627盐酸贝尼地平片珠海优润医药科技有限公司4CYHS2501626钆塞酸二钠注射液广州康臣药业有限公司4CYHS2501625米库氯铵注射液浙江恒研医药科技有限公司4CYHS2501624左氧氟沙星片常州兰陵制药有限公司4CYHS2501622利丙双卡因乳膏广东泰恩康制药厂有限公司4CYHS2501621玻璃酸钠滴眼液北京仁众药业有限公司4CYHS2501620艾拉莫德片江苏悦兴药业有限公司4CYHS2501616氧(液态)四川盈德万华气体有限公司4CYHS2501615阿达帕林凝胶浙江寰领医药科技有限公司4CYHS2501614孟鲁司特钠片重庆药友制药有限责任公司4CYHS2501613二甲双胍恩格列净片(I)涿州东乐制药有限公司4CYHS2501618佩玛贝特片湖南科伦制药有限公司4CYHS2501610二十碳五烯酸乙酯软胶囊博瑞制药(苏州)有限公司4CYHS2501609盐酸乙哌立松片湖南九典制药股份有限公司4CYHS2501607甲磺酸溴隐亭片广州大光制药有限公司4CYHS2501606达格列净二甲双胍缓释片(III)北京四环科宝制药股份有限公司4CYHS2501603达格列净二甲双胍缓释片(I)北京四环科宝制药股份有限公司4CYHS2501602双氯芬酸二乙胺乳胶剂杭州朱养心药业有限公司4CYHS2501598阿达帕林凝胶唐山红星药业有限责任公司4CYHS2501604乳酸钠林格注射液湖南先施制药有限公司4CYHS2501588艾曲泊帕乙醇胺片鲁南贝特制药有限公司4CYHS2501586匹维溴铵片浙江恒研医药科技有限公司4CYHS2501593恩格列净片东北制药集团沈阳第一制药有限公司4CYHS2501590富马酸伏诺拉生片山东普瑞曼药业有限公司4CYHS2501584注射用头孢唑肟钠浙江恒研医药科技有限公司4CYHS2501597注射用头孢唑肟钠浙江恒研医药科技有限公司4CYHS2501596阿哌沙班片广东彼迪药业有限公司4CYHS2501594注射用吗替麦考酚酯四川科瑞德制药股份有限公司4CYHS2501585盐酸米诺环素泡沫剂上海则正医药科技股份有限公司4CYHL2500089倍氯米松福莫特罗吸入气雾剂合肥力成药业有限公司4CYHL2500088盐酸米诺环素泡沫剂深圳珐玛易药品科技有限公司4CYHL2500087进口申请药品名称企业注册分类受理号司替戊醇胶囊Biocodex5.1JXHS2500056司替戊醇胶囊Biocodex5.1JXHS2500055镥[177Lu] 特昔维匹肽注射液Novartis Pharma Schweiz AG5.1JXHS2500054帕博利珠单抗注射液Merck Sharp & Dohme LLC3.1JXSS2500051TQJ230注射液Novartis Pharma AG1JXHL2500103177Lu-HuJ591单抗注射液Telix Pharmaceuticals (Innovations) Pty Ltd1JXSL2500069Mezagitamab注射剂Takeda Development Center Americas, Inc.1JXSL2500067Mezagitamab注射剂Takeda Development Center Americas, Inc.1JXSL2500066VHB937注射用浓溶液Novartis Pharma AG1JXSL2500065中药相关申请药品名称企业注册分类受理号TFA003片杭州康恩贝制药有限公司2.1CXZL2500028百令胶囊杭州中美华东制药有限公司2.3CXZL2500027百令胶囊杭州中美华东制药有限公司2.3CXZL2500026注：绿色字体部分为潜在首仿品种；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

申请上市临床申请

100 项与盐酸特比萘芬相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02219	盐酸特比萘芬	D01AE15 D01BA02	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
甲癣	澳大利亚	Novartis Pharmaceuticals Australia Pty Ltd.	2003-12-22
体癣	澳大利亚	Novartis Pharmaceuticals Australia Pty Ltd.	2003-12-22
股癣	澳大利亚	Novartis Pharmaceuticals Australia Pty Ltd.	2003-12-22
足癣	美国	GlaxoSmithKline Consumer Healthcare Ltd.	1999-03-09
皮肤真菌病	中国	山东安弘制药有限公司	1997-01-01
皮肤念珠菌病	日本	Sun Pharmaceutical Industries Ltd.	1993-07-02
真菌病	日本	Sun Pharmaceutical Industries Ltd.	1993-07-02
癣	日本	Sun Pharmaceutical Industries Ltd.	1993-07-02
花斑癣	日本	Sun Pharmaceutical Industries Ltd.	1993-07-02
头癣	美国	Novartis Pharmaceuticals Corp.	1992-12-30

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
红斑	临床1期	美国	Moberg Pharma AB	2017-10-15
粘膜念珠菌病	临床阶段不明	美国	Novartis AG	2001-08-31
口腔念珠菌病	临床阶段不明	美国	Novartis AG	2001-08-31
HIV感染	临床阶段不明	美国	Novartis AG	2001-08-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05279846 (Company_Website) 人工标引	临床3期	甲癣	384	MOB-015	蓋憲範夢築顧窪網構窪(築廠範襯淵鏇遞鑰顧膚) = 淵膚夢壓簾選膚齋簾醖選鏇構淵網獵積願衊繭 (憲齋鹽獵襯壓繭簾淵鬱 ) 更多	不佳	2025-01-10
NCT03244280 (phase 1 maximal usage trial, Pubmed \| Antimicrob Agents Chemother)	临床1期	甲癣	20	MOB015B	蓋艱窪夢膚廠築糧襯膚(醖淵窪衊網鑰蓋鏇繭膚) = Adverse events (five patients), such as headache (n = 3), seasonal allergy (n = 1), and neck pain (n = 1), were considered unrelated to MOB015B; no application site reactions or study discontinuations due to an adverse event were observed. 獵選鏇淵膚糧壓鑰鑰遞 (鑰襯醖餘淵糧淵餘襯蓋 )	积极	2024-08-19
NCT02859519 (Pubmed \| J Am Acad Dermatol) 人工标引	临床3期	甲癣	-	MOB-015	構顧窪鏇憲淵獵壓鑰醖(廠觸鹹範餘鬱製築鏇糧) = 餘膚衊蓋製襯願襯壓餘鏇襯鑰遞膚範鬱淵壓鏇 (蓋膚鏇憲憲範憲醖窪鏇 ) 更多	非优	2021-07-01
NCT02859519 (Pubmed \| J Am Acad Dermatol) 人工标引	临床3期	甲癣	-	vehicle	構顧窪鏇憲淵獵壓鑰醖(廠觸鹹範餘鬱製築鏇糧) = 糧鏇鹹淵壓齋鹽簾廠鏇鏇襯鑰遞膚範鬱淵壓鏇 (蓋膚鏇憲憲範憲醖窪鏇 ) 更多	非优	2021-07-01
Corporate Publications 人工标引	临床3期	甲癣	452	Terbinafine Hydrochloride	鏇網艱襯鹹醖積築願憲(窪襯齋膚窪願淵鑰觸鏇) = 網鹹積遞簾鏇憲襯製繭淵鹽艱襯淵繭淵範構鏇 (夢夢鹽齋窪鑰觸窪膚範 ) 更多	非劣	2020-06-25
Corporate Publications 人工标引	临床3期	甲癣	452	ciclopirox	鏇網艱襯鹹醖積築願憲(窪襯齋膚窪願淵鑰觸鏇) = 艱糧顧蓋積壓範顧淵淵淵鹽艱襯淵繭淵範構鏇 (夢夢鹽齋窪鑰觸窪膚範 ) 更多	非劣	2020-06-25